Celgene's Bet on Epizyme Pays Off

Celgene and Epizyme got a big boost this week when Epizyme's EPZ-5676 met an important milestone.

Jan 11, 2014 at 3:10PM

A healthy payment from big biotech Celgene Corporation (NASDAQ:CELG) helped Epizyme Inc. (NASDAQ:EPZM) make one of the biggest moves in biotech so far this year.

News that Epizyme Inc.'s EPZ-5676 met its proof of concept milestone in phase 1 dosing trials triggered a $25 million payment from Celgene Corporation, and shares spiked more than 80% this past week. But that move isn't just good for Epizyme Inc. investors, it's also a win for Celgene Corporation given its equity stake in the company.

EPZM Chart

EPZM data by YCharts

Betting on big ideas

Few are bigger than oncology powerhouse Celgene Corporation, particularly when it comes to treating the blood cancer lymphoma. Celgene's Revlimid is one of oncology's top sellers, with Celgene forecasting it will generate sales of over $4 billion in 2013. Across Celgene's Revlimid, Abraxane, Vidaza, and Pomalyst, Celgene is guiding investors to expect full year sales of $6.2 billion for 2013.

But Celgene recognizes it's going to have to keep innovating if it wants to see that franchise grow. So, it's been spreading money around to lock up promising new drugs. It has inked deals potentially worth hundreds of millions with emerging cancer biotech companies OncoMed, blubird bio, and Epizyme Inc..

The Epizyme collaboration extends Celgene's push into epigenetics, giving Celgene overseas rights to Epizyme's EPZ-5676. That drug halts activity of the DOT1L protein that is associated with acute leukemias, including mixed lineage leukemia, or MLL.

The compound is about as early stage as you can get. In fact, all of Epizyme's candidates are fledgling given its most advanced drug has been in phase 1 studies for less than a year.

So, why is Celgene so interested in this emerging company? Because epigenetics offers an intriguing approach to battling disease that could allow a single molecule to affect multiple cancer genes. This specific targeting may allow EPZ-5676 to kill MLL cells without killing non-MLL cells -- a big benefit, especially in young patients.

Dealmaking its way through clinic

Among Epizyme Inc.'s C-Suite leaders are Robert Gould, its CEO, and Jason Rhodes, its President. Gould came to Epizyme after serving as a Director of Novel Therapeutics, a research institute backed by MIT and Harvard. Prior to that position, Gould spent 20 years at Merck, where he was Vice President of External Research at Merck Research Laboratories.

Rhodes made a name for himself as Alnylam's dealmaker; building collaborations that helped make Alnylam into one of 2013's best performers. Since joining Epizyme in 2010, Rhodes and Gould have landed partnerships with Eisai, GlaxoSmithKline, (NYSE:GSK) and Celgene.

Eisai paid Epizyme Inc. $6 million upfront and agreed to as much as $200 million in additional milestones and double digit royalties to license drugs targeting epigenetic enzyme EZH2, which is associated with Lymphoma. So far, that deal has added $30 million in payments to Epizyme's balance sheet.

The GlaxoSmithKline deal included $20 million upfront as part of payments that could eventually total more than $650 million. So far, Epizyme has banked roughly $40 million from Glaxo through its work on HMT inhibiting drugs.

And the Celgene collaboration, which gave Celgene the overseas rights to EPZ-5676, included an upfront payment to Epizyme of $65 million. The success in the proof-of-concept of EPZ-5676 means Celgene has paid Epizyme $90 million so far and more could come given another $135 million in milestone payments are tied to the compound.

A Fool-ishly attractive win, win

Celgene is likely smiling broadly because of Epizyme Inc.'s success, but not just because the drug will advance further into human trials. It's also smiling because of a savvy decision to take a 12.5% ownership stake in Epizyme when the deal was first established.  Celgene paid $25 million for convertible shares and when Epizyme went public last June, Celgene bought another 66,666 shares and converted those preferred shares into common stock.  That resulted in Celgene owning more than 3.3 million shares in Epizyme, or 10% of its fully diluted equity. Given Epizyme's eye popping run this month, that means Celgene's stake in Epizyme is worth roughly $50 million more than it was in December and that makes Epizyme's success an even better win, win for the two companies.

Two more important cancer fighting companies hoping for a win, win

The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

 

Todd Campbell has no position in any stocks mentioned.  Todd owns E.B. Capital Markets, LLC.  E.B. Capital's clients may or may not have positions in the companies mentioned.  Todd also owns Gundalow Advisor's, LLC.  Gundalow's clients do not have positions in the companies mentioned.. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers